APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. - Wikidata - wikimedia - TriplyDB

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

http://www.wikidata.org/entity/Q39752513

about

Twenty Years of PSA: From Prostate Antigen to Tumor Marker A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer Urinary biomarkers for prostate cancer Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes Emerging critical role of molecular testing in diagnostic genitourinary pathology How Precisely Can Prostate Cancer Be Managed?Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease Novel biomarkers for prostate cancer including noncoding transcripts.Novel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer.The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer.Novel diagnostic biomarkers for prostate cancer.Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.A multiplex assay to measure RNA transcripts of prostate cancer in urine.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.Non-Coding RNAs: Functional Aspects and Diagnostic Utility in Oncology Can urinary PCA3 supplement PSA in the early detection of prostate cancer?Progensa PCA3 test for prostate cancer detection.Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.Target-specific capture enhances sensitivity of electrochemical detection of bacterial pathogens.Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.Urinary Volatile Organic Compounds for the Detection of Prostate Cancer Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.RNA biomarkers to facilitate the identification of aggressive prostate cancer Genome-wide association study identifies genetic determinants of urine PCA3 levels in men.Prostasomes as a source of diagnostic biomarkers for prostate cancer.Diagnostic potential for urinary proteomics.Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.The present and future of prostate cancer urine biomarkers.

P2860

Q24564782-592328B8-82CA-48F0-89A7-4F01AF5A25BB Q24569630-E067CD35-C5B1-4651-890F-351FED4CD72C Q24606772-EB3C6574-94D0-46B7-A7B2-431C4092E0DF Q24629083-F55E4A64-4598-4355-B3E5-F2651F430262 Q26767044-81C0CA72-C7DD-422E-B2AE-DCCD4B1DD091 Q27009110-67C3B2D3-DF68-49E9-BC2B-1A1F831D71A1 Q27010695-485A7870-2F52-40DA-BDAD-7221F34B4806 Q27021371-378105A8-ECC0-40AF-BD4E-0222D2B2D4E1 Q28078942-AA3356DF-BAA6-4D31-A4C1-38844AA5E867 Q28085419-D362CB99-884D-483E-BB66-3CCE4E2C824A Q33449075-B943B421-FF4B-4EC5-8B70-1F3591DB7905 Q33515231-1B0CA1C7-F7BC-4558-AB32-176FC9FA082D Q33728046-F08BFDE6-0621-47CC-8D33-66ED6EFAE4B0 Q33909660-65698647-170A-4134-B0D9-5369AE4C2319 Q33922385-C57DFC0C-48D8-481A-9E88-77811B7AF5B3 Q34231678-5CB6EC4A-EE7E-40DB-B38A-31C3131DFCCE Q34296258-21C69802-9514-4AD9-89BF-2DE5E297C8C7 Q34411717-88424CF6-DD67-4BFF-8D9C-76B411840028 Q34429720-AC164AD9-3ADB-4DBB-B2FB-67A376F5514B Q34536729-A1357FC4-020C-4D9D-809E-4ED7920CFF9A Q34605730-2DA326EC-A2E1-44A4-8E02-FC8785F0D6D7 Q34692263-0B70CED5-4B04-42B5-8612-E819E1BAA587 Q34692442-097B87AD-E23C-4E03-88D1-FC13737569BC Q34825819-7889CDF9-F49D-4589-9516-92E1A1CCE54C Q34984413-8E33B7FD-6D17-4CD9-96C0-71C31C19074C Q35598927-9E75FED6-7FB2-4844-BB39-D77482160855 Q35632848-D07E8D6B-EE12-41C7-9830-0D631B04465A Q35771276-517AB815-D893-4127-8E47-80F74D03E14F Q35849909-ADEC7906-BA34-4BDA-850C-A1FDEBC9E0BC Q36190604-EFDFA76F-5D94-4930-9ACE-DECD46916521 Q36260364-43D18973-70D0-4893-B550-4264D4290E70 Q36730598-C31386F8-2E05-4061-9512-E0C7CD0D59FB Q36737927-9B90C191-C82D-4AF7-9946-84BD995B958E Q36745677-CC372105-DF5B-4261-839B-02E7A9FC48AE Q36772249-A600F682-1EFF-4249-B0CF-726D6B2D384A Q36784513-CEF03FFF-B3B0-4710-8A77-7602FA2EC876 Q36886346-23DEC5F3-80A7-4CD1-84EC-9A483484A356 Q36907574-E5362C20-5E01-4A63-A97A-F1E6CE42CA51 Q36931205-977D7410-BED8-4F71-B6BE-2791F104303C Q37007392-0663DC0E-B22E-4FCB-B0A4-95701CA3858D

P2860

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

http://www.wikidata.org/entity/Q39752513

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

APTIMA PCA3 molecular urine te ...... diagnosis of prostate cancer.

@en

APTIMA PCA3 molecular urine te ...... diagnosis of prostate cancer.

@nl

type

label

APTIMA PCA3 molecular urine te ...... diagnosis of prostate cancer.

@en

APTIMA PCA3 molecular urine te ...... diagnosis of prostate cancer.

@nl

prefLabel

APTIMA PCA3 molecular urine te ...... diagnosis of prostate cancer.

@en

APTIMA PCA3 molecular urine te ...... diagnosis of prostate cancer.

@nl

P1433

Q39752513-C5D126B4-72AE-40A8-A899-8E09E4C17068

P1476

Q39752513-E69418B8-664F-4996-9AA8-6C73215FC3B7

P2093

Q39752513-0C9CC571-A271-4FD9-AFD0-44B2B23E05F0

Q39752513-11AA652B-52CD-4DB7-BE6D-0EA0F6540402

Q39752513-128F4433-7766-4839-A09F-DFFDD1CF0676

Q39752513-234E2C38-96A1-4694-9D6C-CC488776FD32

Q39752513-6EEF2AD5-EF8C-4B12-BD80-0C924A1DDDCE

Q39752513-7243DD86-3041-4A77-8669-9E0AC73CF41E

Q39752513-84553E2A-2A0F-4704-8693-76D3E37BC761

Q39752513-95C2CEA9-D867-445B-A9A3-F37EE6627EE6

Q39752513-9CF89D74-5008-4EAE-9E81-E1ADCEC50953

Q39752513-A2CA54A8-A819-48BF-B6C0-96A7DA0C3746

P304

Q39752513-983ADA31-70B3-4574-8B92-3809918FAA82

P31

Q39752513-68F159C1-7AD1-4F5A-9712-1CE96E4B3F07

P356

Q39752513-AC49D75E-972A-465D-9C85-651A30983C49

P407

Q39752513-ECE37E56-9F83-49F3-BDF7-C188DC32EBE2

P433

Q39752513-2A077AB5-ABF0-4C73-8933-4ED503B3EFD7

P478

Q39752513-35D9F8D4-9C84-42B4-9DB9-32D90DF8A56E

P577

Q39752513-3B089E6D-8A58-4F1D-90B0-E173C5CDCB3F

P5875

Q39752513-1E18BEE6-C60D-47F1-8FB9-D9FF7857BA05

P698

Q39752513-17F8034A-F866-4DBA-B827-689DCA5BE910

P356

CLINCHEM.2005.063289

P1433

Clinical Chemistry

P1476

APTIMA PCA3 molecular urine te ...... diagnosis of prostate cancer.

@en

P2093

Amy Blase

http://www.w3.org/2001/XMLSchema#string

Craig Clark

http://www.w3.org/2001/XMLSchema#string

Harry Rittenhouse

http://www.w3.org/2001/XMLSchema#string

Ina Lim Deras

http://www.w3.org/2001/XMLSchema#string

Jack Groskopf

http://www.w3.org/2001/XMLSchema#string

Jeannette Mathis

http://www.w3.org/2001/XMLSchema#string

Jimmykim Pham

http://www.w3.org/2001/XMLSchema#string

Leonard S Marks

http://www.w3.org/2001/XMLSchema#string

Maria Luz Macairan

http://www.w3.org/2001/XMLSchema#string

Michelle Cass

http://www.w3.org/2001/XMLSchema#string

P304

1089-1095

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1373/CLINCHEM.2005.063289

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7152177

http://www.w3.org/2001/XMLSchema#string

P698

16627561

http://www.w3.org/2001/XMLSchema#string